Metabolex and Astellas, to identify potential drug candidates by examining genes associated with insulin resistance and obesity

September 19, 2007 / Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that Astellas Pharma Inc. has begun high-throughput screening against an additional target from Metabolex’s proprietary human gene database. Astellas is working to identify potential drug candidates by examining genes associated with insulin resistance and obesity... Metabolex's Press Release -